Українська Русский English

ISSN 2522-9028 (Print)
ISSN 2522-9036 (Online)
DOI: https://doi.org/10.15407/fz

Fiziologichnyi Zhurnal

is a scientific journal issued by the

Bogomoletz Institute of Physiology
National Academy of Sciences of Ukraine

Editor-in-chief: V.F. Sagach

The journal was founded in 1955 as
1955 – 1977 "Fiziolohichnyi zhurnal" (ISSN 0015 – 3311)
1978 – 1993 "Fiziologicheskii zhurnal" (ISSN 0201 – 8489)
1994 – 2016 "Fiziolohichnyi zhurnal" (ISSN 0201 – 8489)
2017 – "Fiziolohichnyi zhurnal" (ISSN 2522-9028)

Fiziol. Zh. 2008; 54(6): 87-99


The role of toll-like receptors inregulation of immune responses innorm and pathology

N.Ya.Spivak, I.M. Bogdanova, N.I.Martyrosova,V.V.Malaytsev.

    D.K. Zabolotnyi Institute of microbiology and virusologyNAS of Ukraine;Diaprofmed, Kyiv, Ukraine;Institute of Human Morphology RAMS, Moscow, RussiaVINITI RAS, Moscow, Russia


Abstract

We have analyzed the recent data about Toll-like receptors (TLRs) that play the most important role in host immune de- fense. TLRs involved in induction and modulation of innate and acquired immunity as the integrators of their reactions. Genetic disorders of TLRs or their signaling pathways components were noticed with different pathologies. TLRs are the ideal molecu- lar target for the therapy of many diseases including inflammatory, autoimmune, allergic and tumor diseases.

References

  1. Свешников П.Г., Малайцев В.В., Киселев В.И.Функции белков теплового шока в системе адаптив-ного иммунитета. Конструирование вакцин //ЖМЭИ. – 2007, №6. –С.108–117.
  2. Симбирцев А.С. Толл-белки: специфические рецеп-торы неспецифического иммунитета // Иммуно-логия. – 2005, №6. – С.368–377.
  3. Спивак Н.Я., Белоцкий С.М., Карлов В.А. /Сепсис:иммунология и иммунокоррекция. – К.:Фитосоциоцентр. – 2007. – 304 с.
  4. Akira S., Takeda K. Toll-like receptor signaling //Nat.Rev.Immunol. – 2004. – 4. – P.499–511.
  5. Alexopoulou L., Holt A.C., Medzhidov R. et al. // Na-ture. – 2001. – 413. –P.732–738.
  6. Arancibia S.A., BeltranC.J., Aguirre I.M. et al. Toll-like receptors are key participants in innate immuneresponses// Biol.Res. – 2007. – 40, №2. – P.97–112.
  7. Baetz A., Frey M., Heeg K. et al. Suppressor ofcytokine signaling (SOCS) proteins indirectly regulatetoll-like receptor signaling in innate immune cells // J.Biol. Chem. – 2004. – 279, № 52. – P.54708–54715.
  8. Banerjee A., Gerondakis S. Coordinating TLR-activatedsignaling pathways in cekks of the immune system//Immunol.Cell Biol. – 2007. – 85, №6. – P.420–424.
  9. 9. Beutler B., Jiang Z., Georgel P. et al. Genetic analysisof host resistence: Toll-like receptor signaling andimmunity at large //Annu. Rev. Immunol. – 2006. – 24. –P.353–389.
  10. 10. Brint E.K., Xu D., Liu H. et al. ST2 is an inhibitor ofinterleukin 1 receptor and Toll-like receptor 4 signalingand maintains endotoxin tolerance // Nat. Immunol. –2004. – 5, №4. – P.373–379.
  11. Burdelya L.G., Krivokrysenko V.I., Tallant T.C. et al.An agonist of toll-like receptor 5 has radioprotectiveactivity in mouse and primate models // Science. – 2008. –320, № 5873. – P.226–230.
  12. Carriere V., Roussel L., Ortega N. et al. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo // Proc.Natl.Acad.Sci.USA. – 2007, 104. – №1. – P.282–287.
  13. Cirl C., Wieser A., Yadav M. et al. Subversion of Toll-like receptor signaling by a unique family of bacterialToll/interleukin-1 receptor domain-containing proteins // Nat.Med. – 2008. – 14, №4. – P.370–372.
  14. Fitzgerald K.A.,Rowe D.C., Grolenbock D.T. Endot-oxin recognition and signal transduction by the TLR4/MD2-complex // Microbes Infection. – 2004. – 6, №15. –P.1361–1367.
  15. Gaspari A.A. Mechanism of action and other potentialroles of an immune response modifier // Cutis. – 2007. –79, Suppl.4. – P.36–45.
  16. Qin J., Qian Y.,Yao J. et al. SIGIRR inhibits interleukin-1 receptor- and toll-like receptor 4 – mediated signalingthrough different mechanisms // J.Biol.Chem. – 2005. –280, №26. – P.25223–25241.
  17. Gupta K., Cooper C. A review of role of CpGoligodeoxynucleotides as toll-like receptor 9 agonists inprophylactic and therapeutic vacciner development ininfectious diseases // Drugs RD. – 2008. – 9, №3. –P.137–145.
  18. Hayashi F., Smith K.D., Ozinsky A. et al. The innateimmune response to bacterial flagellin is mediated byToll-like receptor 5 // Nature. – 2001. – 410, № 6832. –P.1099–1103.
  19. 19. Horng T., Barton G.M., Flavell R.A. et al. The adaptormolecule TIRAP provides signaling specificity for Toll-likereceptors // Ibid. – 2002. – 420, № 6913. – P.772–777.
  20. 20. Hutti J.E., Turk B.E., Asara J.M. IkappaB kinasa betaphosphorylates the K63 deubiquitinase A20 to causefeedback inhibition of the NF-kappaB pathway //Mol.Cell.Biol. – 2007. – 27, №21. – P.7451–7461.
  21. Kim Y.M., Brinkmann M.M., Paquet M.E. et al.UNC93B1 delivers nucleotide-sensing toll-lire receptorsto endolysosomes // Nature. – 2008. – 452, № 7184. –P.234–238.
  22. Kobayashi K., Hernandez L.D., Galan J.E. et al. IRAK-M is a negative regulator Toll-like receptor signaling //Cell. – 2002. – 110, №2. – P.191–202.
  23. Krishnan J., Selvarajoo K., Tsuchiya M. et al. Toll-likereceptor signal transduction// Exp.Molec.Med. –2007. –39, №4. – P.421–438.
  24. Lasker M.V., Nair S.K. Intracellular TLR signaling: astructural perspective on human disease // J.Immunol. –2006. – 177, №1. – P.11–16.
  25. Lee E.Y., Yim J.J., Lee H.S. et al. Dinucleotide repeatpolymorphism in intron II of human Tolllike receptor 2gene and susceptibility to rheumatoid arthritis //Int.J.Immunogenet. – 2006. – 33, №3. – P.211–215.
  26. Lemaitre B. The road to Toll // Nat.Rev.Immunol. –2004. – 4, №7. – P.521–527.
  27. Mantovani A., Locati M., Polentarutti N. et al. Extra-cellular and intracellular decoys in the tuning ofinflamatore cytokines and Toll-like receptors: the newentry TIR8/SIGIRR // J.Leukoc. Biol. – 2004. – 75,№5. – P.738–742.
  28. Martin H.J., Lee J.M., Walls D. et al. Manipulation ofthe toll-like receptor 7 signaling pathway by Epstein –Barr virus // J.Virol. – 2007. – 81, №18. – P.9748–9758.
  29. 29. Miller R.L., Meng T.C., Tomai N. the antiviral activityof Toll-like receptor 7 and 7/8 agonists // Drug NewsPerspect. – 2008. – 21, №2. – P.69–87.
  30. 30. Mitchell J.A., Paul – Clark M.J., Clarke G.W. et al.Critical role of toll-like receptors and nucleotideoligomerisation domain in the regulation of health anddisease // J.Endocrinol. – 2007. – 193, №3. – P.323–330.
  31. Murad Y.M., Clay T.M., Lyerly H.K. et al. CPG-7909(PF-3512676, ProMune): toll-like receptor 9 agonist incancer therapy // Expert Opin.Biol.Ther. – 2007. – 7,№8. – P.1257–1266.
  32. Noppert S.J., Fitzgerald K.A., Hertzog P.I. The role oftype 1 interferons in TLR responses // Immunol.Cell Biol. –2007. – 85, №6. – P.446–457.
  33. Novak N., Yu C.F., Bussmann C. et al. Putative asso-ciation of a TLR9 promoter polymorphism winh atopiceczema // Allergy. – 2007. – 62, №7. – P.766–772.
  34. O’Neill L.A., Bowie A.G. The family of five: TIR-do-main-containing adaptors in Toll-like receptor signalling/Nat.Rev.Immunol. – 2007. – 7, №5. – P.353–364.
  35. Parker L.C., Prince L.R., Sabroe I. Translational mini-reviews series on Toll-like receptors: Networksregulated by Toll-like receptors mediate innate andadaptive immunity // Clin.Exp.Immunol. – 2007. – 147,№2. – P.199–207.
  36. Plitas G., Burt B.M., Nguyen H.M. et al. Toll-likereceptor 9 inhibition reduces mortality in polimicrobialsepsis // J.Exp.Med. – 2008. – 205, №6. – P.1277–1283.
  37. Rescigno M., Matteoli G. Lamina propria dendritic cells:For whom the bell TOLLs? // Eur.J.Immunol. – 2008. –38, №6. – P.1483–1486.
  38. Sabroe I., Read R.C., Whyte M.K.B. et al. Toll-likereceptors in health and disease: complex questionsremain // J.Immunol. – 2003. – 171, №4. – P.1630–1635.
  39. 39. Schmidt C. Immune system’s Toll-like receptors havegood opportunity for cancer treatment // J.Nat.Canc.Inst. – 2006. – 98, №9. – P.574–575.
  40. 40. Seya T., Akazawa T., Tsujita T. et al. Role of Toll-likereceptors in adjuvant-augmented immunity // Evid BasedComplement Alternat.Med. – 2006. – 3, №1. – P.31–38.
  41. Sun S., Rao N.L.,Veneable J. et al. TLR7/9 antago-nists as therapeutics for immune-mediated inflammatorydisorders // Inflamm.Allergy Drug Targets. – 2007. – 6,№ 4. – P. 223–235.
  42. Tran N., Koch A., Berkels R. et al. Toll-like receptor 9expression in murine and human adrenal glands and pos-sible implications during inflamation// J.Clin. Endocrinol.Metab. – 2007. – 92, №7. – P.2773–2783.
  43. Trinchieri G., Sher A. Cooperation on Toll-like receptorsignal in innate immune defence// Nature Rev.Immunol. –2007. – 7, №7. – P.179–190.
  44. Tsan M.F., Gao B. Endogenous ligands of Toll-likereceptors // J. Leucocyte Biol. – 2004. – 76, №3. –P.514–519.
  45. Turer E.E., Tavares R.M., Mortier E. et al. HomeostaticMyD88-dependent signals cause lethal inflammation inthe absence of A20// J.Exp.Med. – 2008. – 205, №2. –P.451–464.
  46. Williams K.L., Lich J.D., Duncan J.A. et al. Thecaterpillar protein monarch-1 is an antagonist of Toll-like receptor-, tumor necrosis factor-alpha-, and Myco-bacterium tuberculosis-induced proinflamatory signals // J. Biol.Chem. – 2005. – 280, №48. – P.39914–39924.
  47. Wolowczuk I., Verwaerde C., Viltrat O. et al. Feedingour immune system: impact on metabolism // Clin.Dev.Immunol. – 2008. – 2008. – P.639–803.
  48. Yoshida H., Jono H., Kai H. The tumor suppressorcylindromatosis (CYLD) acts as a negative regulatorfor toll-like receptor 2 signaling via negative cross-talkwith TRAF6 and TRAF7 // J. Biol.Chem. – 2005. –280, №49. – P.41111–41121.
  49. 49. Zacharowski K., Zacharowski P.A., Koch A. et al. Toll-like receptor 4 plays a crucial role in the immune-adre-nal response to systemic inflammatory response syn-drome // Proc.Natl.Acad.Sci.USA. – 2006. – 103, №16.– P.6392–6397.
  50. 50. Zhou C., Kang X.D., Chen Z. A synthetic Toll-likereceptor 2 ligand decreases allergic immune responsesin a mouse rhinitis model sensitized to mite allergen//J.Zhejiang Univ.Sci.B. – 2008. – 9, №4. – P.279–285.

© National Academy of Sciences of Ukraine, Bogomoletz Institute of Physiology, 2014-2019.